Novartis says Leqvio launch will feature a 'modest initial ramp,' but blockbuster potential awaits

As Novartis creeps toward losing exclusivity for some big-selling medicines, the drugmaker is counting on new launches to replace lost sales and fuel growth. One such launch is cholesterol drug Leqvio, and execs said Wednesday the company is laying the groundwork for a medicine with "multiblockbuster potential."